Author(s):

Nadia Oviedo

Introduction:

The Asia Pacific facial injectable market—comprising sales of botulinum toxin (BTX), hyaluronic acid (HA) dermal fillers, particle and polymer fillers (PPFs), and collagen fillers—will grow strongly through 2014 due to increased physician adoption of profitable facial injectable treatments in their practices and growing patient demand for less invasive cosmetic procedures. Media reports have magnified certain adverse events associated with BTX and PPF treatments, however, which will discourage some individuals from seeking these procedures. Furthermore, many patients are deterred by the cost and inconvenience of repeat BTX and HA dermal filler treatments: in some cases, two to three visits are required for optimal results. The strict regulatory approval processes in some countries will also impede new product releases. Nonetheless, a high aesthetic consciousness in the Asia Pacific region will fuel continued demand for cosmetic procedures, including facial injectable treatments. Given the tight labor market during the global economic recession, a number of individuals will seek facial injectable treatments to enhance their appeal as job candidates. The large pool of patients in the Asia Pacific region represents a significant opportunity for revenue potential in the facial injectable market.

Questions Answered in This Report:

  *   In September 2009, Sculptra was listed under the Public Benefits Scheme in Australia, resulting in the subsidization of treatment for patients suffering from HIV-related lipoatrophy. How did this affect market growth during the recession? What impact did the approval of reimbursement have on the competitive landscape within the Australasian PPF segment?

  *   The collagen filler markets across the Asia Pacific countries will become obsolete to varying degrees by the end of the forecast period, following the withdrawal of Allergan from the market in 2010. Which facial injectable market segments will benefit from the decline of the collagen filler market? Which competitors will remain in the collagen filler market? How will the exit of Allergan affect revenues and average selling prices (ASPs) in the collagen filler market?

  *   Q-Med's Restylane became the first HA dermal filler approved for aesthetic use in China in January 2009. How has this product approval changed the competitive landscape in the Chinese HA dermal filler market? How will the launch of Restylane in China affect unit volumes and aggregate ASPs over the forecast period?

  *   Within the Asia Pacific, the Australasian and Chinese markets for facial injectables will sustain the fastest growth through 2014. What country-specific factors will support the growth of these markets in particular? Which markets were more resilient during the global economic crisis? Was overall growth supported more by BTX sales or by expanding use of dermal fillers?

Scope:

Regions covered: Australia, New Zealand, Japan, China, Taiwan, and South Korea

Segmentation: Our analysis uses the following segmentation of the market:

• Facial injectable products
  • BTX
  • HA dermal fillers
  • PPFs (Australia, New Zealand, Japan, China, and Taiwan only)
  • Collagen fillers (Australia, New Zealand, Japan, China, and Taiwan only)

Market forecast features: Based on primary research with industry professionals, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, and market values over a 7-year period (2008–2014).

Competitive analysis: We provide a detailed analysis of the competitive landscape in the market, as well as market shares and qualitative discussions of the leading competitors in each market segment.